← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Centene grew premium and service revenue, but medical-cost and Marketplace resets pushed the year into a GAAP loss.
The read at a glance✓ Audited against SEC data
- Growth — +20.0% premium and service revenue to $174.58BOK
- Profitability — Net income -301.9% to -$6.67BWatch
- Cash quality — Free cash flow +981.8% to $4.32BNote
- Margins — Gross margin -359 bps; operating margin -655 bpsWatch
- Balance sheet — Debt -6.2%; equity -24.4%Watch
- Insiders — 2 open-market buys / 3 sellsNote
Business
Centene is a managed-care company focused on government-sponsored and subsidized health coverage. Its FY2025 operating segments were Medicaid, Medicare, Commercial, and Other, with Marketplace insurance inside Commercial and specialty, clinical, vision, dental, behavioral health, and centralized services inside Other.
Where the revenue comes from
Fiscal 2025, as CENTENE CORP reports it. History and quarterly detail are in the app.
- Medicaid$90.2B
- Commercial$42.0B
- Medicare$37.2B
- Other$5.1B
Leadership changes
From CENTENE CORP's own filings, the day they're filed.
- Theodore Pienkos · Chief Accounting Officer · appointmenteff. 2026-03-18
- Kate Casso · Chief Accounting Officer · appointmenteff. 2026-03-18
- James E. Murray · departureeff. 2024-03-29
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-07-29
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CENTENE CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.